Key statistics
As of last trade Exelixis Inc (EXEL:NSQ) traded at 36.17, -1.17% below its 52-week high of 36.60, set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.80 |
---|---|
High | 36.39 |
Low | 35.80 |
Bid | 36.16 |
Offer | 36.19 |
Previous close | 35.61 |
Average volume | 2.12m |
---|---|
Shares outstanding | 285.58m |
Free float | 280.99m |
P/E (TTM) | 22.69 |
Market cap | 10.17bn USD |
EPS (TTM) | 1.57 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 17:03 GMT.
More ▼
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
- Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
- Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
- Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
- Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
- Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
More ▼